Evaluation of the Effects of Dyslipidemia on Hearing in Patients with Type 2 Diabetes Mellitus.

Modernization has led to change in life style and physical inactivity which are playing a major role in increasing the number of people with diabetes and dyslipidaemia, Different types of hearing loss in diabetic patients have been reported which shows progressive, gradual, bilateral sensorineural loss. The primary aim of the present study is to evaluate the effects of dyslipidemia on hearing in patients with type 2 diabetes mellitus. A comparative study was conducted where patients were divided into 4 groups-Type II diabetes mellitus with dyslipidemia,Type II diabetes mellitus with normal lipid profile, Only Dyslipidemia,Normal subjects. A total of 128 participants were enrolled in the study. The Diabetes patient was determined by the FBS, PPBS and Hba1c levels. Dyslipidemia determined by LDL,HDL,VLDL.Patients with Type 2 diabetes mellitus and dyslipidaemia was evaluated for the presence of hearing loss with the help of PTA. Prevalence of hearing loss among patients with Diabetes and Dyslipidaemia was 65.7%, 40.6% in Type II DM with normal lipid profile patients, 18.75% in patients with dyslipidaemia. Statistically significant association of hearing loss was noted in patients with diabetes mellitus and dyslipidaemia. Although hearing loss is multifactorial, control of the risk factors like dyslipidaemia in diabetes mellitus definitely halt the process of auditory damage. As observed from this study, poor glycaemic control, associated other co-morbidities were contributing factors for hearing loss. Healthy life style with early recognition of these diseases helps in preventing further damage.

Invasive Aspergillosis of Nose and Paranasal Sinus in COVID-19 Convalescents: Mold Goes Viral?

Invasive Aspergillosis of the paranasal sinus is an aggressive illness, particularly affecting the immunocompromised and rarely, the immunocompetent. COVID-19 has been shown to cause a derangement of immune parameters both during active infection and the convalescent period. A retrospective study was done from June 10th 2021 to September 10th 2021 on patients who underwent endoscopic debridement of the involved sinuses for post COVID fungal rhinosinusitis. This study included the patients who had Aspergillus infection from the isolated nasal tissue samples. Patient's information, complaints, history of COVID infection, clinical findings, investigations and treatment details were obtained from the records. 13 patients with post-COVID Invasive Fungal Sinusitis were identified. Symptom onset usually occurred within 1 month of COVID 19 diagnosis in all the patients. Nasal obstruction (84%) and headache (61%) were the most common symptoms. Computerized tomography imaging showed maxillary sinus involvement in all patients followed by ethmoid sinus in 76% of patients. Microbiological diagnosis and histopathological confirmation of Aspergillus species was done. All 13 patients underwent endoscopic debridement of the involved sinuses followed by anti-fungal therapy with Posaconazole. All responded well to the treatment with no recurrence till date. Admist an infinite number of Mucormycosis cases in this era of COVID-19 pandemic, we experienced a surge of Aspergillus infection during this second wave. Presentation at a young age, with no known co-morbidities, with minimal symptoms and history of COVID-19 infection are some of the important aspects to be considered in this series. A better morbidity outcome is expected when early detection and treatment is made in patients with post Covid-19 viral illness with Aspergillosis of nose and paranasal sinus.

New Visionary in Upper Airway Surgeries-THRIVE, a Tubeless Ventilation.

THRIVE stands for Transnasal Humidified Rapid Insufflation Ventilatory Exchange. Usage of THRIVE technique is common in emergency settings and of late its usage in upper airway surgeries is gaining popularity. (1) To determine the operative time, total anaesthesia time, safety and efficacy of THRIVE in patients undergoing upper airway surgeries for varied pathologies. (2) To assess the surgeon's satisfaction and patients post-operative comfort. An observational study was from May 2019 to Oct 2020. Study was conducted through a detailed proforma which consists of patient demographic details, physical status, co-morbidities and various domains to assess the safety and efficacy of THRIVE. A total of 32 patients were divided into four groups depending on the type of surgery. We had 18 patients in microlaryngeal excision, six in direct laryngoscopy and biopsy, four in tracheostomy and four in balloon dilatation for subglottic stenosis groups. The mean operation time was 16 ± 2 min in the first three groups and 29 ± 0.8 in the fourth group. All the patients underwent successful surgeries without any episodes of desaturation, without complications and with good surgical satisfaction. THRIVE with appropriate safety precautions can be tried in patients undergoing various upper airway surgeries of short duration. All the patients in our study maintained stable vital parameters throughout the surgery. Initial results with the use of THRIVE as per our study and other studies are definitely encouraging to use THRIVE in upper airway surgeries with varied pathologies.

Hearing Loss-a Camouflaged Manifestation of COVID 19 Infection.

The symptomatology of novel Severe Acute Respiratory Syndrome Corona virus type 2 infection runs the entire gamut of mild to moderate and serious illness among the affected individuals. As listed in recent literature, respiratory, cardiovascular, gastrointestinal, olfactory and gustatory systems are commonly involved. With the growing knowledge about the disease, varied manifestations have been identified and lately, otorhinolaryngology dysfunctions in COVID 19 have been described. Hearing loss in COVID era is one of the emerging areas of concern and calls for further research in the field for the better understanding and treatment of this entity. This study was designed to assess the audiological profile among 100 mild to moderately affected COVID-19 individuals, so as to make a contribution to the emerging literature on otologic manifestations in COVID 19. In our case series, high frequency hearing loss and referred OAE was noted among significant number of COVID 19 positive patients. This was even observed in patients without any otologic symptoms. Hence, early identification and intervention if required helps to give a better quality of life to the patient.